| pubmed-article:21840433 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0013557 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0020557 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0015689 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0018684 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0033080 | lld:lifeskim |
| pubmed-article:21840433 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:21840433 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:21840433 | pubmed:dateCreated | 2011-8-15 | lld:pubmed |
| pubmed-article:21840433 | pubmed:abstractText | Patients with increased triglyceride levels compared to those with normal levels are at higher risk for coronary heart disease. In patients with severe (?500 mg/dl) hypertriglyceridemia (SHTG), clinical trials have demonstrated that prescription ?-3 fatty acids (P-OM3s) 4 g/day can decrease triglyceride levels by 45%. However, the precise health and economic benefits of decreasing SHTG with P-OM3 are unknown. We used the previously validated Archimedes model to simulate a 20-year trial involving subjects 45 to 75 years old with SHTG. The trial consisted of an intervention arm (P-OM3 4 g/day) and a control arm. Simulation results for the control arm indicated that subjects with SHTG are at about 2 times higher risk for myocardial infarction than those with normal triglyceride levels. Using estimates from previous epidemiologic studies and meta-analyses with OM3s, the model predicted 29% to 36% decreases in various measurements of adverse cardiac events for the intervention arm. The model also predicted a decrease in ischemic stroke of 24% (95% confidence interval 15 to 33). For the 20-year simulated trial, the cost per quality-adjusted life-year gained for the currently available P-OM3 approved by the Food and Drug Administration was $47,000. Results remained robust under different clinical assumptions. In our model P-OM3 was effective in decreasing triglyceride levels and cardiovascular disease risk in patients with SHTG. In conclusion, P-OM3 medication is cost effective in our simulated trial and comparable to other cost-effective cardiovascular interventions. | lld:pubmed |
| pubmed-article:21840433 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21840433 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21840433 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21840433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21840433 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21840433 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:21840433 | pubmed:issn | 1879-1913 | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:JohnsonSusanS | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:JacobsonTerry... | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:SamuelStuartS | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:BlumenfeldIan... | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:StoneGlendaG | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:ArondekarBhak... | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:PeskinBarbara... | lld:pubmed |
| pubmed-article:21840433 | pubmed:author | pubmed-author:AlperinPeterP | lld:pubmed |
| pubmed-article:21840433 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21840433 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21840433 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21840433 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:21840433 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21840433 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21840433 | pubmed:pagination | 691-7 | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:meshHeading | pubmed-meshheading:21840433... | lld:pubmed |
| pubmed-article:21840433 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21840433 | pubmed:articleTitle | Estimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemia. | lld:pubmed |
| pubmed-article:21840433 | pubmed:affiliation | Archimedes, Inc., San Francisco, California, USA. stuart.samuel@archimedesmodel.com | lld:pubmed |
| pubmed-article:21840433 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21840433 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
